Comparison of emedastine 0.05% or nedocromil sodium 2% eye drops and placebo in controlling local reactions in subjects with allergic conjunctivitis

European Journal of Ophthalmology

Volumn 12, Issue 4, 2002, Pages 262-266

  Orfeo, Vincenzo ^a   Vardaro, A ^a   Lena, P ^a   Mensitieri, I ^a   Tracey, M ^a   De Marco, R ^a  

^a Unità di Oftalmologia   (Italy)

Author keywords

Allergen; Allergic conjunctivitis; Conjunctival allergen challenge; Emedastine difumarate; Nedocromil sodium

Indexed keywords

ANTIHISTAMINIC AGENT; EMEDASTINE; EYE DROPS; HISTAMINE H1 RECEPTOR ANTAGONIST; NEDOCROMIL SODIUM; PLACEBO;

ADOLESCENT; ADULT; ALLERGIC CONJUNCTIVITIS; ALLERGY; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; DRUG EFFICACY; ERYTHEMA; FEMALE; HISTAMINE RELEASE; HUMAN; MALE; PRIORITY JOURNAL; PRURITUS; TREATMENT OUTCOME;

EID: 0036657063     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210201200402     Document Type: Article

References (13)

1. Allansmith MR, Ross RN. Ocular allergy and mast cell stabilizers. Surv Ophthalmol 1986; 30: 229-44.
2. Stock EL, Pendleton RB. Pharmacological treatment of ocular allergic disease. Int Ophthalmol Clin 1993; 33: 47-58.
3. Sorkin EM, Ward A. Ocular Sodium Cromoglycate. An overview of its therapeutic efficacy in allergic eye disease. Drugs 1986; 31: 131-48.
4. Seamone C, Jackson WB. Immunology of the external eye. In: Tasman W, ed. Duane's Clinical Ophthalmology, vol. 4. Philadelphia: Lippincott Williams & Wilkins, 1999; 1-52.
5. Sharif NA, Su SX, Yanni JM. Histamine receptor-subtype affinities, selectivities, and potencies of emedastine, a novel H1-selective antagonist, and other ocularly employed antihistamines. Drug Dev Res 1994; 33: 448-53.
6. Yanni JM, Stephens DJ, Parnell DW, Spellman JM. Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use. J Ocul Pharmacol 1994;10: 665-75.
7. Alcon Laboratories (UK) Ltd. Summary of Product Characteristics - Emadine 0.05% w/v Eye Drops, 27 Jan 1999.
8. Robertson SM. Efficacy and safety of emedastine ophthalmic solution compared to levocabastine ophthalmic suspension in alleviating allergic conjunctivitis. Proc. International Congress of Ophthalmology, Amsterdam, Netherlands, Jun 21-26, 1998.
9. Alexander M, Roln LI, Yang WH. Comparison of topical nedocromil sodium and oral terfenadine for the treatment of seasonal allergic conjunctivitis. Clin Ther 1999; 21: 1900-7.
10. El Hennawi M. A double-blind placebo controlled group comparative study of ophthalmic sodium cromoglycate and nedocromil sodium in the treatment of vernal keratoconjunctivitis. Br J Ophthalmol 1994; 78: 365-9.
11. Kjellman N-IM, Stevens MT. Clinical experience with Tilavist: An overview of efficacy and safety. Allergy 1995; 50: 14-22.
12. Aichane A. Campbell AM, Chanel I, et al. Precision of conjunctival provocation tests in right and left eyes. J Allergy Clin Immunol 1992; 1: 49-55.
13. Moqbel R, Cromwell O, Walsh GM, Wardlaw AJ, Kurlak L, Kay AB. Effects of nedocromil sodium (Tilade) on the activation of human eosinophils and neutrophils and the release of histamine from mast cells. Allergy 1988; 43: 268-76.